12:00 AM
Apr 17, 2000
 |  BC Week In Review  |  Company News  |  Deals

Biogen, CV Therapeutics deal

CVTX received a $6.5 million milestone from BGEN triggered by the completion in February of a Phase II trial of CVTX's...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >